Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07701512
PHASE2

Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients

Sponsor: Tanta University

View on ClinicalTrials.gov

Summary

To assess the effect of Febuxostat on clinical outcomes and biomarkers of oxidative stress and inflammation in patients with conservatively managed intracranial hemorrhage.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

46

Start Date

2025-11-20

Completion Date

2027-01-30

Last Updated

2026-07-14

Healthy Volunteers

No

Interventions

DRUG

Febuxostat 40 mg

Participants in this arm will receive Febuxostat at a dose of 40 mg orally once daily for a duration of three months, administered in addition to the standard traditional therapy for conservatively managed intracranial hemorrhage

DRUG

Standard medical treatment

Participants in this arm will receive only the standard traditional medical guidelines and therapy for conservatively managed intracranial hemorrhage for a duration of three months

Locations (1)

Neurosurgery department Mansoura university hospitals

Al Mansurah, Dakahlia Governorate, Egypt